Providence Therapeutics Holdings Inc

We are a clinical-stage biotechnology company focused on drug development and platform development.

Providence’s mRNA and NextGen LNP platform offer an end-to-end solution for designing codon-optimized ultrapure mRNA that can be formulated in application optimized LNP. The Providence proprietary NextGen LNP, consists of rationally designed lipids that have been tested for suitability for programs in oncology, infectious diseases and gene delivery.

Our scalable, efficient platform demonstrates differentiated capabilities in mRNA design, manufacturing, and formulation processes, as well as specific organ and tissue targeting.